MDxHealth (NASDAQ:MDXH) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of MDxHealth (NASDAQ:MDXH) to a sell rating in a report issued on Saturday morning.

MDXH has been the subject of a number of other reports. William Blair cut shares of MDxHealth from an “outperform” rating to a “market perform” rating in a report on Thursday, May 14th. Lake Street Capital set a $3.00 price objective on MDxHealth and gave the stock a “buy” rating in a research note on Friday. TD Cowen reissued a “buy” rating and set a $1.50 price objective (down from $7.00) on shares of MDxHealth in a research report on Thursday, May 14th. Finally, BTIG Research cut their price objective on MDxHealth from $7.00 to $4.00 and set a “buy” rating for the company in a research report on Thursday, May 14th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, MDxHealth currently has a consensus rating of “Hold” and a consensus target price of $2.83.

MDxHealth Trading Up 5.9%

Shares of MDxHealth stock opened at $0.86 on Friday. The firm has a fifty day simple moving average of $0.48 and a 200-day simple moving average of $1.75. The stock has a market capitalization of $42.35 million, a price-to-earnings ratio of -1.19 and a beta of 1.42. MDxHealth has a 1-year low of $0.40 and a 1-year high of $5.33.

MDxHealth (NASDAQ:MDXH) last posted its earnings results on Thursday, August 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.01. The firm had revenue of $27.21 million during the quarter, compared to analyst estimates of $26.14 million. As a group, research analysts predict that MDxHealth will post -0.6 earnings per share for the current year.

Hedge Funds Weigh In On MDxHealth

Several large investors have recently bought and sold shares of the stock. Intesa Sanpaolo Wealth Management acquired a new stake in MDxHealth in the 4th quarter worth $36,000. Lido Advisors LLC bought a new position in shares of MDxHealth during the 3rd quarter worth about $48,000. Squarepoint Ops LLC acquired a new position in shares of MDxHealth during the fourth quarter valued at about $51,000. Jefferies Financial Group Inc. acquired a new position in shares of MDxHealth during the third quarter valued at about $53,000. Finally, Balyasny Asset Management L.P. bought a new stake in shares of MDxHealth in the fourth quarter valued at about $68,000.

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.